Using activated carbon nanoparticles to decrease the genotoxicity and teratogenicity of anticancer therapeutic agents

Journal of Nanoscience and Nanotechnology

Volumn 10, Issue 12, 2010, Pages 8603-8609

  Zhong, Yang ^a   Shuzheng, Ma ^b   Yingge, Zhang ^b  

^a Research Laboratory of Neurobiology   (China)

^b Maternal and Children Healthy Science Institute   (China)

Author keywords

Active carbon nanoparticles; Chromosome aberration; Micronucleus test; Mitomycin C; Teratogenicity test

Indexed keywords

ACTIVE CARBON; CHROMOSOME ABERRATION; MICRONUCLEUS TEST; MITOMYCIN C; TERATOGENICITY TEST;

ACTIVATED CARBON; CHEMOTHERAPY; CHROMOSOMES; DRUG INTERACTIONS; NANOPARTICLES; TOXIC MATERIALS;

TESTING;

ALKYLATING AGENT; CHARCOAL; MITOMYCIN; NANOPARTICLE;

ANIMAL; ARTICLE; CELL LINE; CHEMISTRY; CONGENITAL MALFORMATION; CRICETULUS; DRUG EFFECT; DRUG SCREENING; FEMALE; FETUS DEVELOPMENT; HAMSTER; HUMAN; MALE; MICRONUCLEUS TEST; MOUSE; MUTAGEN TESTING; PREGNANCY; RAT; STOMACH TUMOR; TUMOR CELL LINE;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE; CELL LINE, TUMOR; CHARCOAL; CRICETINAE; CRICETULUS; FEMALE; FETAL DEVELOPMENT; HUMANS; MALE; MICE; MICRONUCLEUS TESTS; MITOMYCIN; MUTAGENICITY TESTS; NANOPARTICLES; PREGNANCY; RATS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952108196     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2010.2492     Document Type: Conference Paper

References (21)

1. X. P. Yang, Antitumor agents, Medical Pharmacology, edited by Z. C. Yang, M. H. Yao, M. X. Jiang, J. Q. Qian, and C. Sun, 4th edn., People's Health Publishers, Beijing, China (2005), pp. 1057-1086.
2. M. J. Ellenhorn, S. Schonwald, G. Ordog, and J. Wasserberger (eds.), Cancer chemotherapeutic agents (cytotoxic drugs), Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning, 2nd edn., Williams & Wilkins, Baltimore, Maryland, USA (1997), Chap. 61, pp. 1321-1355.
3. X. Wang, L. Yang, Z. Chen, and D. M. Shin, CA Cancer J Clin. 58, 97 (2008).
4. H. Liang, P. Wang, X. N. Wang, N. Liu, X. Yue, D. C. Wang, J. C. Wang, and X. S. Hao, Chin. J. Surg. 41, 274 (2003).
5. T. Takahashi, A. Hagiwara, M. Shimotsuma, K. Sawai, and T. Yamaguchi, World J. Surg. 19, 565 (1995).
6. T. Takhashi, K. Sawai, A. Hagiwara, S. Takahashi, K. Seiki, and H. Tokuda, Semin. Surg. Oncol. 7, 378 (1991).
7. M. Ohgaki, T. Takahashi, K. Sawai, Prophylaxis with Mitomycin C Bound to Carbon Particles Against Peritoneal Recurrence of Gastric Cancer, edited by M. Nishi, H. Sugano, and T. Takahashi, International Gastric Cancer congress, Kyoto, March-April (1995).
8. J. Fass, M. Jasen, and Zengel, Arch. Chir. Suppl. Kongressbd. 115, 1363 (1998).
9. H. R. Rosen, G. Jatzko, and S. Repse, J. Clin. Oncol. 16, 2733 (1998).
10. Q. L. Qu, Y. G. Zhang, and L. Sun, Bull. Acad. Mil. Med. Sci. 28, 552 (2004).
11. Q. L. Qu, Y. G. Zhang, L. Z. Yang, and L. Sun, Chin. J. Oncol. 28, 257 (2006).
12. L. Sun, Y. G. Zhang, and L. Z. Yang, Bull. Acad. Mil. Med. Sci. 29, 349 (2005).
13. L. Z. Yang, L. Sun, and Y. G. Zhang, Biotechnol. 16, 525 (2005).
14. Q. L. Qu and Y. G. Zhang, Lett. Biotechnol. 15, 45 (2004).
15. M. Kruk and M. Jaroniec, J. Phys. Chem. B 106, 4732 (2002).
16. L. Z. Yang and Y. G. Zhang, Chin. J. Cancer Prev. Treat. 15, 1548 (2008).
17. X. X. Huang and X. R. Chen, The Test Methods of the Mutagenesis, Teratogenicity and Algogenesis of Environmental Chemicals, Hangzhou Scientific and Technological Publishers, Hangzhou (1985), pp. 195-235.
18. Bureau of Pharmacy of the People's Republic of China, A Compilation of the Directory Principles for Preclinical Studies of New Drugs (Western Medicine), Health Ministry of China, Beijing (1993), pp. 211-215.
19. N. J. Huang, Hereditas 6, 26 (1984).
20. R. A. Freitas, Jr., Navigation, Basic Capabilities, Nanomedicine, edited by Robert A. Freitas, Landes Biosciences, U. S. A. (1999), pp. 209-274, Chap. 8, Vol. 1.
21. L. Sun, Y. G. Zhang, and L. Z. Yang, Bull. Acad. Milit. Med. Sci. 29, 349 (2005).